MedTrace Logo

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

NCT00984477 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-12-04

No results posted yet for this study

Summary

The purpose of the study is to determine how quickly AZD5122 is absorbed into and cleared by the body when given to healthy, non smoking males at different dose levels. This is a 2 part study, in Part B a single group of subjects will be given both an oral dose and intravenous microdose of AZD5122 at a specialist unit. For part B there is no placebo treatment given.

Conditions

  • Healthy

Interventions

DRUG

AZD5122

A single dose of oral suspension

DRUG

Placebo

A single dose of oral suspension

DRUG

AZD5122

A single intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Andrew Sparrow, BSc, BMedSci, BM,BS · AstraZeneca Clinical Pharmacology Unit, Queens Medical Centre, Nottingham NG7 2UH

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Completion
2009-11-30

Countries

  • United Kingdom

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984477 on ClinicalTrials.gov